Bellucci R, Sala R, De Propris M S, Cordone I, de Fabritiis P
Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy.
Leuk Lymphoma. 1999 Nov;35(5-6):471-81. doi: 10.1080/10428199909169611.
We have studied the in vitro effect of IFN-alpha and bcr-abl antisense oligodeoxynucleotides (As ODN) alone and in combination with the aim of enhancing the antileukemic activity of the two single agents and evaluating whether the two agents in combination might restore the adherence capacity of chronic myeloid leukemia (CML) progenitors to preformed stroma. We have also correlated the increased adhesion found after in vitro treatment with the expression of adhesion molecules on leukemic progenitors. Incubation of the BV173 cell line with escalating doses of IFN-alpha (100-10000 U/ml) showed a colony growth inhibition between 10 and 30%. IFN-alpha and junction-specific As ODN in combination showed a greater antiproliferative effect compared to that observed with the two agents used alone. In particular, As ODN at a concentration of 40 microg/ml in combination with IFN-alpha at 100 and 1000 U/ml showed a greater inhibitory effect compared to that obtained with IFN-alpha only. Addition of As ODN to IFN-alpha at 10000 U/ml did not result in a greater BV173 inhibition. In a further set of experiments, primary cells from 16 CML patients at diagnosis were incubated with 40 microg/ml of J-spec As ODN, several control ODNs and IFN-alpha at 1000 U/ml alone and in combination. A significantly greater elimination of CML progenitors was found after treatment with the combination of IFN-alpha and J-spec As ODN, compared to any other treatment group, confirmed also by a more marked effect on p210 expression. The deficient adhesion of CML progenitors on human preformed stroma was restored at levels similar to that of normal bone marrow cells after treatment with IFN-alpha and/or J-spec As ODN, while the phenotypic analysis showed that the combined treatment increased significantly the expression of CD49b and CD62L on CML CD34+ cells. However, when the expression of adhesion molecules was blocked with specific monoclonal antibodies, only CD49d (expressed on more than 90% of CML CD34+ cells) appeared to influence the functional activity of adhesion molecules. In conclusion, IFN-alpha and bcr-abl As ODN in combination exert a marked in vitro antileukemic activity and could be a useful approach for in vitro purging of CML cells prior to autologous transplantation.
我们研究了单独使用以及联合使用干扰素-α(IFN-α)和bcr-abl反义寡脱氧核苷酸(As ODN)的体外效应,目的是增强这两种单一药物的抗白血病活性,并评估联合使用这两种药物是否可能恢复慢性粒细胞白血病(CML)祖细胞对预先形成的基质的黏附能力。我们还将体外处理后发现的黏附增加与白血病祖细胞上黏附分子的表达相关联。用递增剂量的IFN-α(100 - 10000 U/ml)孵育BV173细胞系,显示集落生长抑制率在10%至30%之间。与单独使用这两种药物相比,IFN-α和连接特异性As ODN联合使用显示出更大的抗增殖作用。特别是,浓度为40μg/ml的As ODN与100和1000 U/ml的IFN-α联合使用时,与仅使用IFN-α相比显示出更大的抑制作用。在10000 U/ml的IFN-α中添加As ODN并未导致对BV173的更大抑制。在另一组实验中,将16例初诊CML患者的原代细胞分别用40μg/ml的J-特异性As ODN、几种对照ODN以及1000 U/ml的IFN-α单独或联合孵育。与任何其他治疗组相比,用IFN-α和J-特异性As ODN联合治疗后发现CML祖细胞的清除明显更多,对p210表达的更显著影响也证实了这一点。用IFN-α和/或J-特异性As ODN治疗后,CML祖细胞在人预先形成的基质上的黏附缺陷恢复到与正常骨髓细胞相似的水平,而表型分析表明联合治疗显著增加了CML CD34 +细胞上CD49b和CD62L的表达。然而,当用特异性单克隆抗体阻断黏附分子的表达时,只有CD49d(在超过90%的CML CD34 +细胞上表达)似乎影响黏附分子的功能活性。总之,IFN-α和bcr-abl As ODN联合使用具有显著的体外抗白血病活性,可能是自体移植前体外清除CML细胞的一种有用方法。